Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Clinical trial NCT07354074 · RECRUITING

Trial details

NCT number: NCT07354074
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive

Start date: 2026-04-28
Primary completion: 2033-02-23
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.